Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics

Abstract

Introduction

The rising cost of cancer drugs may make treatment unaffordable for some patients. Patients often rely on drug manufacturer-administered Pharmaceutical Assistance Programs (PAPs) to obtain drugs and reduced or no cost. The overall usage of PAPs within cancer care delivery is unknown.

Methods

We included all cancer patients across an academically affiliated, integrated health system in North Carolina during 2014 (N = 8591). We identified the subset of patients receiving PAP assistance to afford one or more cancer drugs, in order to calculate the proportion of patients receiving PAP assistance, and the retail value of the assistance.

Results

Among 8591 cancer patients, 215 unique patients submitted a total of 478 successful PAP requests for cancer drugs. 40% of PAP-utilizing patients were uninsured, 23% had Medicaid coverage, 20% had Medicare coverage, 2% were dual Medicare/Medicaid eligible, and 14% were commercially insured. Among all cancer patients who received medical treatment, 6.0% required PAP assistance, whereas 10.6% receiving an oral agent required PAP assistance. The proportion receiving PAP assistance varied substantially by drug, ranging from <1% of patients (e.g. carboplatin, methotrexate) to 50% of patients (e.g. ponatinib, temsirolimus). The majority of the retail value obtained was for oral agents, including $1,556,575 of imatinib and $1,449,633 of dasatinib, which were the two drugs with the highest aggregate retail value.

Conclusions

A substantial proportion of cancer patients receive private charitable assistance to obtain standard-of-care treatments. This includes patients with federal and private insurance, suggesting an inability of patients to meet cost-sharing requirements.

Keywords

Pharmaceutical foundations charity care financial assistance oral drugs

Get full access to this article

View all access options for this article.

References

Scalo

Rascati

. Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 35–44.

Bach

. Limits on medicare’s ability to control rising spending on cancer drugs. N Engl J Med 2009; 360: 626–633.

Bach

. Monthly and median costs of cancer drugs at the time of FDA approval 1965–2015, MSKCC Center for Health Policy and Outcomes, 2015. Available at: www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs, 2015.

Claxton

et al.

Health benefits in 2015: stable trends in the employer market. Health Aff Proj Hope 2015; 34: 1779–1788.

Zafar

. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst 2016; 108. Available at: www.ncbi.nih.gov/pubmed/26657334.

Key Facts on Corporate Foundations, The Foundation Center, 2011. Available at: foundationcenter.issuelab.org/resource/key_facts_on_corporate_foundations_2011, 2011.

Visante . How copay coupons could raise prescription drug costs by $32 billion over the next decade Pharmaceutical Care Management Association, 2011.

Chauncey

Mullins

Tran

et al.

Medication access through patient assistance programs. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2006; 63: 1254–1259.

Choudhry

Lee

Agnew-Blais

et al.

Drug company-sponsored patient assistance programs: a viable safety net?

Health Aff Proj Hope 2009; 28: 827–834.

10.

Carroll

. Pharmaceutical patient assistance programs: don’t look a gift horse in the mouth or there’s no such thing as a free lunch. J Manag Care Pharm 2007; 13: 614–616.

11.

Choudhry

Lee

Agnew-Blais

et al.

Patient assistance programs: information is not our enemy. Health Aff Proj Hope 2009; 28: 843–844.

12.

Felder

Lal

Bennett

et al.

Cancer patients’ use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center. Community Oncol 2011; 8: 279–286.

13.

Crisp

et al.

The University of North Carolina’s Health Care Pharmacy Assistance Progam. N C Med J 2014; 75: 303–309.

14.

Sarrafizadeh

Waite

Hobson

et al.

Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2004; 61: 1816–1820.

15.

Dusetzina

Basch

Keating

. For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach. Health Aff Proj Hope 2015; 34: 584–591.

16.

Dusetzina

Keating

. Mind the gap: why closing the doughnut hole is insufficient for increasing medicare beneficiary access to oral chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34: 375–380.

17.

Raborn

Pelletier

Smith

et al.

Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis. Am J Manag Care 2012; 18: SP57–SP64.

18.

Bennette

Richards

Sullivan

et al.

Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff Proj Hope 2016; 35: 805–812.

19.

Trompeter

Havrda

. Impact of obtaining medications from pharmaceutical company assistance programs on therapeutic goals. Ann Pharmacother 2009; 43: 469–477.

20.

Felder

Palmer

Lal

et al.

What is the evidence for pharmaceutical patient assistance programs? A systematic review. J Health Care Poor Underserved 2011; 22: 24–49.

21.

Johnson

. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 2006; 63: S13–S17.

22.

Chisholm

DiPiro

. Pharmaceutical manufacturer assistance programs. Arch Intern Med 2002; 162: 780–784.

23.

Buell

Gesme

. Survey of provider perspectives on patient assistance programs. J Oncol Pract Am Soc Clin Oncol 2009; 5: 184–187.

24.

Schencker

. Lifesavers or kickbacks? Critics say patient-assistance programs help keep drug prices high. Mod Healthc 2015; 45: 20–22.

25.

Howard

. Drug companies’ patient-assistance programs–helping patients or profits? N Engl J Med 2014; 371: 97–99.

26.

Rubino

et al.

Academy of managed care pharmacy guide to pharmaceutical payment methods, Version 1.0, 2007. Available at: www.amcp.org/WorkArea/DownloadAsset.aspx?id=9856 2007.